Dr Alex Zhavoronkov is the CEO of Insilico Medicine, a Baltimore-based leader in next-generation artificial intelligence and blockchain technologies for drug discovery, biomarker development and ageing research. He co-founded LongeVC and is the Head of its Advisory Board.
At Insilico, Alex pioneered generative adversarial networks and reinforcement learning techniques for generating novel molecular structures with the desired properties. He set up the R&D centres in six countries, including Korea, Russia and Taiwan, and launched multiple biomarker initiatives, including YoungAI. Next to advising for LongeVC, Alex is one of the Longevity Science Foundation's Visionary Board members.
Before founding Insilico Medicine, Alex worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation, and YLabs.AI. He also created AgeNet.net, a platform with contests, hackathons, and resources for ageing biomarker development competitions, and led the diversity.AI initiative.
Since 2012, he has published more than 80 peer-reviewed research papers and books, including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy." He is also the co-organiser of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life, one of Europe's most significant drug discovery industry events.
Dr Zhavoronkov holds two Bachelor's degrees from Queen's University, a Master's in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University.